ALTERNATING CHEMORADIOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL PLUS BLEOMYCIN BY CONTINUOUS INFUSION FOR LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE

被引:38
|
作者
AZLI, N
ARMAND, JP
RAHAL, M
WIBAULT, P
BOUSSEN, H
ESCHWEGE, F
SCHWAAB, G
GASMI, J
BACHOUCHI, M
CVITKOVIC, E
机构
[1] INST GUSTAVE ROUSSY, UNITE LA GRANGE VILLEJUIF, F-77176 VILLEJUIF, FRANCE
[2] INST SALAH AZAIZ, TUNIS, TUNISIA
[3] CTR ANTI CANC BENBADIS, CONSTANTINE, ALGERIA
关键词
D O I
10.1016/0959-8049(92)90005-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom. From February 1986 to November 1987 30 consecutive patients with very advanced local disease were entered in a programme with chemotherapy-radiotherapy (CT-RT) alternation after a thorough work-up to eliminate the possibility of distant metastases. Protocol: two cycles of cisplatin 100 mg/m2 day 1, bleomycin 15 mg intravenously day 1 and 16 mg/m2 per day by continuous infusion days 1-5; 5-fluorouracil (5-FU) 650 mg/m2 per day by continuous infusion days 1-5 4 weeks apart. This was followed by two series of high-energy radiotherapy, 35 Gy/3.5 weeks, with a third chemotherapy cycle in between. 27 men and 3 women were treated, the median age was 37 years (range 17-71) and the mean WHO performance status was 1 (range 0-3). TNM classification: 15 T4, 9 T3, 6 T2, 28 N3 and 2 N2c. 18 patients had nodes larger than 8 cm and 24 had bulky bilateral cervical nodes. Toxicity for this protocol was moderate, nausea and vomiting being the main side-effects. Results after two CT cycles were 3 complete responses (CR; 10%), 22 partial responses (PR; 73%), 2 disease stabilisations, 2 progressions, and 1 patient inevaluable. Of the 30 patients, 27 patients completed the CT-RT protocol, 2 patients died before radiotherapy and 1 refused treatment after 2 days on protocol. 25 patients were in CR 3 months after the end of radiotherapy. As of August 1991, with a median follow-up of 55 months (range 43-63), there are 17 patients alive, 2 of them with active disease and 15 are NED (2 after salvage therapy).
引用
收藏
页码:1792 / 1797
页数:6
相关论文
共 50 条
  • [41] A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol
    Chen, Yun
    Zhu, Zhengfei
    Zhao, Weixin
    Li, Ling
    Ye, Jinjun
    Wu, Chaoyang
    Tang, Huarong
    Lin, Qin
    Li, Jiancheng
    Xia, Yi
    Li, Yunhai
    Zhou, Jialiang
    Zhao, Kuaile
    RADIATION ONCOLOGY, 2018, 13
  • [42] Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type
    Hasbini, A
    Mahjoubi, R
    Fandi, A
    Chouaki, N
    Taamma, A
    Lianes, P
    Cortès-Funes, H
    Alonso, S
    Armand, JP
    Cvitkovic, E
    Raymond, E
    ANNALS OF ONCOLOGY, 1999, 10 (04) : 421 - 425
  • [43] CONTINUOUS-INFUSION CISPLATIN AND BOLUS 5-FLUOROURACIL IN COLORECTAL-CARCINOMA
    POSNER, MR
    BELLIVEAU, JF
    WEITBERG, AB
    SABBATH, K
    WIEMANN, MC
    CUMMINGS, FJ
    CALABRESI, P
    CANCER TREATMENT REPORTS, 1987, 71 (10): : 975 - 977
  • [44] Neoadjuvant chemotherapy with 5-Fluorouracil infusion and Cisplatin for untreated locally advanced squamous cell carcinoma of head and neck
    Choi, KK
    Kim, MJ
    Kim, KW
    Cho, YS
    Bang, YJ
    Heo, DS
    3RD ASIAN CONGRESS ON ORAL AND MAXILLOFACIAL SURGERY, 1996, : 189 - 193
  • [45] Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma
    Cho, EK
    Lee, WK
    Lim, DY
    Bang, SM
    Park, DK
    Park, YH
    Kwon, OS
    Choi, DJ
    Shin, DB
    Lee, JH
    Lee, TH
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (03) : 348 - 352
  • [46] Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus
    Takagawa, Ryo
    Kunisaki, Chikara
    Makino, Hirochika
    Kosaka, Takashi
    Ono, Hidetaka A.
    Akiyama, Hirotoshi
    Shimada, Hiroshi
    DISEASES OF THE ESOPHAGUS, 2009, 22 (06) : 482 - 489
  • [47] Phase II study of induction chemotherapy and concomitant chemoradiotherapy with cisplatin and continuous infusion 5-fluorouracil (PF) for anal carcinoma
    Freire, J. G.
    Trindade, M. C.
    Barata, A. M.
    Venancio, J.
    Claro, I.
    Fernandes, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] TREATMENT OF ADVANCED SQUAMOUS-CELL CARCINOMA OF THE SKIN WITH CISPLATIN, 5-FLUOROURACIL, AND BLEOMYCIN
    SADEK, H
    AZLI, N
    WENDLING, JL
    CVITKOVIC, E
    RAHAL, M
    MAMELLE, G
    GUILLAUME, JC
    ARMAND, JP
    AVRIL, MF
    CANCER, 1990, 66 (08) : 1692 - 1696
  • [49] CAPECITABINE VERSUS CONTINUOUS 5-FLUOROURACIL IN THE TREATMENT OF LOCALLY ADVANCED ANAL CARCINOMA WITH CHEMORADIOTHERAPY: A RETROSPECTIVE COHORT STUDY
    Meulendijks, D.
    Dewit, L.
    Tomasoa, N. B.
    van Tinteren, H.
    Beijnen, J. H.
    Schellens, J. H. M.
    Cats, A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (04) : 770 - 771
  • [50] Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma
    Sasaki, Ken
    Uchikado, Yasuto
    Omoto, Itaru
    Arigami, Takaaki
    Osako, Yusaku
    Noda, Masahiro
    Okumura, Hiroshi
    Maemura, Kosei
    Higashi, Ryutaro
    Yoshiura, Takashi
    Natsugoe, Shoji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 581 - 587